2. Signaling Pathways
  3. Neuronal Signaling
  4. CaMK

CaMK

Calmodulin-dependent protein kinases; Calmodulin-dependent kinases

CaMK

Related Products

PDF 0.47 MB

The Ca2+/calmodulin-dependent kinase (CaMK) family has been recognized as a key mediator in living organisms and various biological processes.

CaMK II is a multifunctional cytoplasmic calcium and calmodulin-dependent protein kinase that phosphorylates and alters the function of a variety of substrates. The CaMK II pathway has been found to regulate the RANKL-induced osteoclast formation via the cAMP-response element binding protein (CREB) pathway.

Among many signaling pathways of proliferation, intracellular calciumol/L has been extensively demonstrated to be very important. In cytoplasm, calciumol/L binds to calmodulin, and then activates the CaMKs which are a family of structurally related serine/threonine protein kinases including CaMKI-IV. CaMKII, a multi functional protein kinase, is ubiquitously involved in many physiological processes including control of cell cycle, apoptosis, gene expression, and neurotransmission.

CaMK Isoform Specific Products:

CaMK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10316
    CaMKI(299-320)
    		Modulator
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis.
    CaMKI(299-320)
  • HY-B0532AS
    Trifluoperazine-d3 dihydrochloride
    		Inhibitor
    Trifluoperazine-d3 (dihydrochloride) is deuterium labeled Trifluoperazine (dihydrochloride). Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis.
    Trifluoperazine-d<sub>3</sub> dihydrochloride
  • HY-P5987
    Calmodulin Kinase IINtide, Myristoylated
    		Inhibitor
    Calmodulin Kinase IINtide, Myristoylated (Myr-CaMKIINtide) is a selective and noncompetitive inhibitor of CaMKII.
    Calmodulin Kinase IINtide, Myristoylated
  • HY-P1479
    Calmodulin-Dependent Protein Kinase II (290-309)
    Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.
    Calmodulin-Dependent Protein Kinase II (290-309)
  • HY-P10282
    Synapsin I-(3-13)
    Synapsin I-(3-13), a substrate for CaMK1, is a glycoprotein. Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals.
    Synapsin I-(3-13)
  • HY-B0532AR
    Trifluoperazine dihydrochloride (Standard)
    		Inhibitor
    Trifluoperazine (dihydrochloride) (Standard) is the analytical standard of Trifluoperazine (dihydrochloride). This product is intended for research and analytical applications. Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis.
    Trifluoperazine dihydrochloride (Standard)
  • HY-P3811
    Autocamtide-3
    Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca2+/calmodulin-dependent kinase II) (CaMK) substrate.
    Autocamtide-3
  • HY-135167
    HOCPCA
    HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability.
    HOCPCA
  • HY-110140
    (E)-KN-93 phosphate
    		Inhibitor 99.85%
    (E)-KN-93 phosphate is an inhibitor for Ca2+/calmodulin-dependent protein kinase II (CaMK II) with IC50 of 9 μM and 3 μM, for CaMKIIδ monomer and CaMKIIδ dodecamer. (E)-KN-93 phosphate binds competitively with Ca2+/CaM, and disrupts their interaction with CaMK II, and thus inhibits the CaMK II activation.
    (E)-KN-93 phosphate
  • HY-15720B
    Glycyl H-1152 hydrochloride
    		Inhibitor
    Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride.
    Glycyl H-1152 hydrochloride
  • HY-P10499
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors.
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
  • HY-P5525
    AC3-I, myristoylated
    		Inhibitor
    AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)
    AC3-I, myristoylated
  • HY-P10071
    CaMKII inhibitory peptide KIIN
    		Inhibitor
    CaMKII inhibitory peptide KIIN is a potent inhibitor of CaMKII.
    CaMKII inhibitory peptide KIIN
  • HY-176149
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
    		Inhibitor
    Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research.
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
  • HY-P10638A
    TAT-CN21 (scrambled)
    		Control
    TAT-CN21 (scrambled) is a control peptide lacking specific targeting activity, used as a negative control for TatCN21 (HY-P10638). TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII).
    TAT-CN21 (scrambled)
  • HY-162860
    FO-4-15
    		Activator
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
  • HY-RS10438
    PHKA2 Human Pre-designed siRNA Set A

    PHKA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PHKA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    PHKA2 siRNA-1: 5 nmol (HPLC)

    PHKA2 siRNA-2: 5 nmol (HPLC)

    PHKA2 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)
    PHKA2 Human Pre-designed siRNA Set A
    PHKA2 Human Pre-designed siRNA Set A
  • HY-111093
    Protein kinase inhibitor 8
    		Inhibitor
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases.
    Protein kinase inhibitor 8
  • HY-P3943
    Calmodulin Dependent Protein Kinase Substrate Analog
    Calmodulin Dependent Protein Kinase Substrate Analog is a Ca2+- and calmodulin (CaM)-dependent protein kinase (CaMK) substrate peptide. Calmodulin Dependent Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases.
    Calmodulin Dependent Protein Kinase Substrate Analog
  • HY-156104
    CaMKIIα-PHOTAC
    		Degrader
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains.
    CaMKIIα-PHOTAC
Cat. No. Product Name / Synonyms Application Reactivity
CaMK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.